Herpferon® (Herpferon®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceInterferon alfa-2b + Acyclovir + LidocaineInterferon alfa-2b + Acyclovir + Lidocaine
Similar drugsTo uncover
  • Herpferon®
    ointment locally externally 
    FIRN M, ZAO     Russia
    • Dosage form: & nbsp
    ointment for topical and topical application
    Composition:
    For 1 g of ointment:

    Active substances: Interferon alfa-2b human recombinant not less than 20 000 ME; acyclovir 30 mg, lidocaine hydrochloride 10 mg.

    Excipients: methylparahydroxybenzoate 2 mg, macrogol 1500 - 290 mg, macrogol 400 - 660 mg.
    Description:Ointment is white or white with a creamy shade of color with a weak specific odor.
    Pharmacotherapeutic group:Antiviral for topical use
    ATX: & nbsp

    D.06.B.B   Antiviral drugs

    Pharmacodynamics:Gerpferon ® - ointment for local and external use - a combined preparation that has antiviral, anti-inflammatory, immunomodulating and analgesic effects.
    Interferon alfa-2b human recombinant has a pronounced antiviral activity (suppresses the replication of the virus in infected cells) and immunomodulating effect (enhancement of phagocytic activity of macrophages in lesion sites).
    Acyclovir has a pronounced antiviral effect. Highly active against Herpes simplex virus type 1 and type 2; a virus that causes varicella and herpes zoster (Varicella zoster).
    Lidocaine has a local anesthetic and moderate antipruritic effect.The combination of active ingredients provides a more pronounced anti-herpetic effect: prevents the formation of new elements of the rash, reduces the likelihood of cutaneous dissemination, accelerates healing, and reduces pain.
    Pharmacokinetics:When using ointment systemic absorption is low: on intact skin - minimal absorption, in blood and urine is not determined, on the affected skin, the absorption is moderate.
    Indications:Primary and recurrent herpetic lesions of the skin and mucous membranes, genital herpes, herpes zoster.
    Contraindications:Hypersensitivity to the components of the drug.
    Pregnancy and lactation:Data on the use of the drug during pregnancy and during lactation are not available. Therefore, the use of the drug in these categories of patients should be only if the expected therapeutic effect exceeds the risk of development of possible side effects.
    Dosing and Administration:The preparation Gerpferon®, ointment for local and external application is applied to the affected skin and mucous membranes with a thin layer 5 times a day at intervals of 4 hours. The duration of treatment is 5-10 days.
    Side effects:It is possible to peel the skin in a place of prolonged application of the ointment.
    Overdose:Cases of drug overdose have not been identified.
    Interaction:The drug is compatible and well combined with anti-inflammatory and immunomodulating medications.
    Special instructions:The effectiveness of drug treatment will be higher the earlier it was started (at the first signs of infection).
    Effect on the ability to drive transp. cf. and fur:Does not affect the ability to drive a vehicle or to perform potentially dangerous activities requiring special attention and quick reactions (working with moving mechanisms, etc.).
    Form release / dosage:
    Ointment for 5 g, 10 g, 30 g.
    Packaging:
    In aluminum tubes with bushon.
    One tube together with instructions for use is placed in a pack of cardboard.
    Storage conditions:The drug is stored at a temperature of 2 to 8 ° C. Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N003324 / 01
    Date of registration:20.03.2009 / 14.08.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:FIRN M, ZAO FIRN M, ZAO Russia
    Manufacturer: & nbsp
    FIRN M, ZAO Republic of Belarus
    Information update date: & nbsp02.04.2017
    Illustrated instructions
      Instructions
      Up